natgillin/translations-raw huggingface dataset:
A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject in need thereof a pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 mg per day. 
Farmaceutski pripravak za upotrebu u liječenju multiple skleroze, naznačen time da se pripravak sastoji od: (a) dimetil fumarata ili monometil fumarata, i (b) jednog ili više farmaceutski prihvatljivih ekscipijenata, pri čemu se pripravak oralnim putem daje osobi kojoj je potrebno liječenje od multiple skleroze, te pri čemu je doza dimetil fumarata ili monometil fumarata koja se daje 480 mg dnevno.
An isolated non-tumoral mesenchymal uterine cervix stem cell obtained by exfoliation of the uterine cervix, wherein said cell: 
Izolirana ne-tumorska mezenhimska matična stanica vrata maternice dobivena eksfolijacijom vrata maternice, pri čemu navedena stanica:
preparing a final compressible blend, by blending the rapidly dispersing granules of step a), a lubricant, the preblend 2 of step c), and a filler, optionally wherein the lubricant is sodium stearyl fumarate and the filler is sugar alcohol or rinsed mannitol; 
pripremanje konačne mješavine pogodne za komprimiranje, miješanjem brzo dispergirajućih granula iz koraka a), lubrikanta, pred-mješavine 2 iz koraka c), i filera, izborno pri čemu je lubrikant natrij stearil fumarat i filer je šećerni alkohol ili isprani manitol;
Form I of clause 9, wherein the Form I is further characterized by a peak at 7.6 to 8.0 degrees. 
Oblik I iz zahtjeva 8, gdje je Oblik I dalje naznačen s pikom na 7,6 do 8,0 stupnjeva.
The use of claim 7, wherein the use is for providing local analgesia, local anesthesia or nerve blockade in a human following laparotomy. 
Uporaba u skladu s patentnim zahtjevom 7, pri čemu je uporaba za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca kod čovjeka nakon laparotomije.
In a most preferred embodiment of the present invention, the system for cell cultivation comprises an external column connected to a bioreactor, wherein the solid support for cultivation of anchorage-dependent cells is located within the external column, and wherein the connection between the external column and the bioreactor comprises a circulation pump. 
U najpoželjnijoj izvedbi ovoga izuma, sustav za uzgoj obuhvaća vanjsku kolonu koja je povezana za bioreaktor, a gdje se kruta potpora za uzgoj stanica koje potrebuju pričvršćivanje nalazi unutar vanjske kolone te gdje poveznica između vanjske kolone i bioreaktora podrazumijeva postojanje cirkulacijske pumpe.
A method for the treatment of diabetes, which comprises administering an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt thereof, to a human being or animal in need thereof. 
15 5. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time namijenjen upotrebi u liječenju dijabetesa.
when the information about compensation type of the current block indicates the edge type, the compensation value corresponds to an edge level, the plurality of compensation values correspond to a plurality of edge levels, and the compensation value corresponding to the edge level is one of the plurality of compensation values, the edge level is one of the plurality of edge levels and determined by comparing the at least one pixel and neighboring pixels of the at least one pixel. 
kada informacija o vrijednosti kompenzacije piksela označava drugi tip koji se odnosi na razine graničnih vrijednosti, određivanje razine granične vrijednosti trenutnog piksela (30) uspoređivanjem vrijednosti trenutnog piksela (30) i vrijednosti susjednih piksela (31, 32, 33, 34, 35. 36 i 37) u deblokiranoj/filtriranoj slici, te zbrajanje vrijednosti kompenzacije trenutnog piksela koja odgovara razini granične vrijednosti i trenutne vrijednosti piksela, te je razina granične vrijednosti jedna od mnoštva graničnih vrijednosti.
G is a single bond. 
G je jednostruka veza,
once the bayonet tube is loaded and the loading system is wound up, the flexible detachable tube (7) is moved in order to load the next tube. 
- kada se bajonetna cijev napuni i sustav za punjenje se namota, odvojiva savitljiva cijev (7) se pomiče radi punjenja sljedeće cijevi.
the activation conditions comprise the addition of a catalytic amount of elastase to the solution containing the autoactivating proelastase protein; and/or 
(b) uvjeti aktivacije obuhvaćaju dodavanje katalitičke količine elastaze u otopinu koji sadrži autoaktivacijski protein proelastazu; i/ili
Also according to above embodiment, the one or more antidiabetic compounds comprised in the pharmaceutical composition may optionally be selected from the group consisting of protein tyrosine phosphatase inhibitors, glutamine-fructose-6-phosphate amidotransferase inhibitors, glucose-6-phosphatase inhibitors, fructose-1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glucagon receptor antagonists, phosphoenolpyruvate carboxykinase inhibitors, pyruvate dehydrogenase kinase inhibitors, alpha-glucosidase inhibitors, inhibitors of gastric emptying, glucokinase activators, GLP-1 receptor agonists, GLP-2 receptor agonists, UCP modulators, RXR modulators, GSK-3 inhibitors, PPAR modulators, metformin, insulin, and a2-adrenergic antagonists. 
Farmaceutska kompozicija proma bilo kojem od patentnih zahtjeva 1-13, naznačena time što takav pojedinačni dozni oblik sadrži jedan ili više antidijabetičnih spojeva koji su izabrani iz grupe koju čine inhibitori protein tirozin fosfataze, inhibitori glutamin-fruktoza-6-fosfat amidotransferaze, inhibitori glukoza-6-fosfataze, inhibitori fruktoza-1,6-bisfosfataze, inhibitori glikogen fosforilaze, antagonisti receptora za glukagon, inhibitori fosfoenolpiruvat karboksikinaze, inhibitori piruvat dehidrogenaza kinaze, inhibitori alfa-glukozidaze, inhibitori pražnjenja želuca, insulin i o2-adrenergični antagonisti.
The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof according to claim 3, wherein R1 represents hydrogen; 
Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 3, naznačen time, da predstavlja vodik;
wherein Y is a solid support and Tr is trityl. 
[image] ili [image], gdje je Y čvrsti nosač, a Tr je tritil.
each R2 is independently H, halogen or C1-C4 straight or branched alkyl; 
Spoj prema zahtjevu 2 gdje R24 je C1-C4 ravni ili razgranati alkil
If the level of inhibition seen at the highest test concentration did not exceed 50%, no potency value was produced and a percentage inhibition value at that concentration was quoted. 
Ako nivo inhibicije koji se javio kod najviše ispitivane koncentracije nije prešao 50%, vrijednost potentnosti nije proizvedena i citiran je postotak vrijednosti inhibicije pri toj koncentraciji.
The present invention also provides for the use of a compound of formula I for the manufacture of a medicament for the treatment of susceptible neoplasms or viral infections. 
Ovaj izum također osigurava upotrebu spoja formule I u proizvodnji lijeka za liječenje osjetljivih novotvorina ili virusnih infekcija.
Suitable salts of the compound include, but are not limited to, acid addition salts, such as those made with hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, carbonic cinnamic, mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benezenesulfonic, p-toluene sulfonic, cyclohexanesulfamic, salicyclic, p-aminosalicylic, 2-phenoxybenzoic, and 2-acetoxybenzoic acid; salts made with saccharin; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; and salts formed with organic or inorganic ligands, such as quaternary ammonium salts. 
Prikladne soli spoja uključuju, ali bez da su time ograničene, kisele adicijske soli, kao što su one dobivene s klornom, bromovodičnom, jodovodičnom, perklornom, sulfatnom, dušičnom, fosfornom, octenom, propionskom, glikolnom, mliječnom piruvatnom, malonskom, jantarnom, maleičnom, fumarnom, jabučnom, vinskom, limunskom, benzojevom, ugljičnom cimetnom, bademovom, metansulfonskom, etansulfonskom, hidroksietansulfonskom, benzensulfonskom, p-toluen sulfonskom, = cikloheksansulfamskom, = salicilnom, = p-aminosalicilnom, 2-fenoksibenzojevom, i 2- acetoksibenzojevom kiselinom; soli dobivene sa saharinom; alkalne metalne soli, kao što su natrijeve i kalijeve soli; soli zemno alkalijskih metala, kao što su kalcijeve i magnezijeve soli; te soli dobivene s organskim ili anorganskim ligandima, kao što su kvaternarne amonijeve soli.
said amino acid substitution is P396L. 
(d) navedena supstitucija na položaju P396 je P396L.
A lyophilized formulation comprising an anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugate (ADC), a sugar, histidine, and a surfactant, wherein said anti-EGFR ADC comprises an anti-EGFR antibody conjugated to an auristatin, wherein the anti-EGFR antibody comprises a heavy chain variable region comprising complementarity domain regions (CDRs) comprising the amino acid sequences set forth in SEQ ID NOS: 15, 16, and 17, and comprises a light chain variable region comprising CDRs comprising the amino acid sequences set forth in SEQ ID NOS: 20, 21, and 22. 
HR P20190672 T1 PATENTNI ZAHTJEVI na Liofilizirana formulacija koja sadrži konjugat protutijela lijeka (ADC) protiv receptora epidermalnog faktora rasta (EGER), šećer, histidin, 1 surfaktant, naznačena time što navedeni anti-EGFR ADC sadrži anti-EGFR protutijelo konjugirano na auristatin, pri čemu anti-EGFR protutijelo sadrži varijabilnu regiju teškog lanca koja sadrži regije koje određuju komplementarnost (CDR-ove) koje sadrže amino aminokiselinske sekvence navedene u SEQ ID NOS: 15, 16, 1 17, 1 sadrži varijabilnu regiju lakog lanca koja sadrži CDR-ove koje sadrže amino aminokiselinske sekvence navedene u SEQ ID NOS: 20, 21,122.
The PET container of claim 12 wherein the second endothermic transition temperature is at least 30° C. higher than the first endothermic glass transition temperature. 
PET posuda iz patentnog zahtjeva 8 gdje je temperatura drugog endotermnog prelaza stakla najmanje 20% C. viša nego temperatura prvog endotermnog prelaza stakla.
A compound according to claim 1, wherein R1 is substituted cycloalkylalkyl, substituted piperazinyl, substituted piperidinyl, substituted indanyloxyalkyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted pyridinylalkyl, substituted pyridinylalkenyl, naphtyl, substituted naphthyl, substituted quinolinyl, substituted isoquinolinyl, or substituted 1H-indol-2-yl, wherein substituted cycloalkylalkyl, substituted piperazinyl, substituted piperidinyl, substituted indanyloxyalkyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted pyridinylalkyl, substituted pyridinylalkenyl, substituted naphthyl, substituted quinolinyl, substituted isoquinolinyl and substituted 1H-indol-2-yl are substituted with R8, R9 and R10. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R1 supstituirani cikloalkilalkil, supstituirani piperazinil, supstituirani piperidinil, supstituirani indaniloksialkil, supstituirani fenil, supstituirani fenilalkil, supstituirani fenoksialkil, supstituirani fenilcikloalkii, supstituirani fenilalkenil, supstituirani piridinilalkil, supstituirani piridinilalkenil, naftil, supstituirani naftil, supstituirani kinolinil, supstituirani izokinolinil, ili supstituirani 1H-indol-2-il, gdje su supstituirani cikloalkilalkil, supstituirani piperazinil, supstituirani piperidinil, supstituirani indaniloksialkil, supstituirani fenil, supstituirani fenilalkil, supstituirani fenoksialkil, supstituirani fenilcikloalkil, supstituirani fenilalkenil, supstituirani piridnilalkil, supstituirani piridinilalkenil, supstituirani naftil, supstituirani kinolinil, supstituirani izokinolinil i supstituirani 1H-indol-2-il, supstituirani s R8, R9 i R10.
After degassing three times, the enamine amide was hydrogenated under 200 psi hydrogen gas at 50°C for 13 h. 
Nakon degasiranja tri puta, enamin amid je hidrogeniran pod 200 psi vodika na 50*C tijekom 13 h.
a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from 
5-člana ili 6-člana monociklička aromatska heterociklička skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od:
The rodent of any one of the preceding claims, wherein the human portion of the chimeric polypeptide comprises a human leader sequence. 
Glodavac iz zahtjeva 1. ili zahtjeva 2. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima glodavca. Glodavac iz bilo kojeg od prethodnih zahtjeva, pri čemu se ljudski dio kimernog polipeptida sastoji od vodećeg ljudskog slijeda.
a polynucleotide encoding a polypeptide having at least 95% sequence identity to (a), wherein the polypeptide has a W or a Y at position 28 and a T at position 44, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11. 
polinukleotid koji kodira polipeptid koji ima najmanje 95 % identičnosti slijeda s (a), gdje polipeptid ima W ili Y na položaju koji odgovara položaju 28 u SEQ ID NO:2 i T na položaju koji odgovara položaju 44 u SEQ ID NO:2, te što polipeptid može vezati miostatin, aktivin A ili GDF-11.
The antibody drug conjugate of claim 3, wherein the peptidyl linker comprises a valine-alanine dipeptide. 
Konjugat protutijelo lijek prema zahtjevu 3, naznačen time što peptidil poveznica sadrži dipeptid valin-alanin.
The compounds wherein R1 is NOR, with R being hydrogen, (C1-6) alkyl or (C1-6) acyl, are prodrugs of the compounds wherein R1 is O. Likewise the compounds wherein R3 is (C1-15) acyl are prodrugs of the corresponding compounds wherein R3 is hydrogen. 
Spojevi gdje R! je NOR, a R je vodik, (C,.6) alkil ili (C,.4) acil, predlijekovi su spojeva gdje R! je O. Isto tako, spojevi gdje R? je (C,.13) acil su predlijekovi odgovarajućih spojeva gdje R* je vodik.
• shock; sepsis; cardiogenic shock; control of leukocyte activation; inhibition or modulation of platelet aggregation; 
• šokom; sepsom; kardiogenim šokom; kontrolom aktivacije leukocita; inhibicijom ili modulacijom agregacije trombocita;
Assay buffer—BSA Diluent/Blocking solution concentrate (3.1.50) diluted 1:15. 
Pufer za test - koncentrat BSA diluent/otopina za blokiranje (3.1.50) razrijeđeno u omjeru 1:15.
deriving an intra prediction mode of a prediction unit by using a Most Probable Mode, MPM, group; generating a prediction block of a current block according to the intra prediction mode; generating a residual block of the current block by inversely quantizing a quantized block using quantization parameter and by inversely transforming the inversely quantized block, wherein the quantized block is generated by inversely scanning quantized coefficient information using an inverse scan pattern determined based on the intra prediction mode and a size of the current block which is equal to or smaller than a size of the prediction unit; and 
generiranje (S1400) rezidualnog bloka tekućeg bloka na osnovi intrapredikcijskog režima i veličine tekućeg bloka; i generiranje (S1500) rekonstruiranog bloka tekućeg bloka korištenjem predikcijskog bloka i rezidualnog bloka gdje je veličina tekućeg bloka jednaka ili manja od veličine predikcijske jedinice i gdje su veličine predikcijskog bloka, rezidualnog bloka i rekonstruiranog bloka jednake veličini transformacijske jedinice i gdje informacije o veličini transformacije sadrže jednu ili više oznaka dijeljene transformacijske jedinice, split_tu_flags, gdje izvođenje intrapredikcijskog režima predikcijske jedinice sadrži:
—CH2—; X4, X5, X6 and X7 are each selected from the group consisting of 
X*, X", Xi X/ su svaki izabran iz grupe koja se sastoji od
The oil, obtained after concentration under vacuum, crystallized upon addition ofEtOH. 
Ulje, dobijeno poslije koncentriranja pod vakuumom, kristalizirano je poslije dodavanja EtOH.
The isolated or purified nucleic acid according to claim 2 comprising the nucleotide sequence of SEQ ID NO: 31, SEQ ID NO: 32, or both SEQ ID NOs: 31 and 32. 
nukleinska kiselina može sadržavati nukleotidni slijed SEQ ID NO: 31, SEQ ID NO: 32, ili i SEQ ID NO: 31 i 32; ili
The compound of claim 11, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Uporaba prema patentnom zahtjevu 1, naznačena time što su kognitivni poremećaji 1 bolesti povezani s RyR izabrani iz grupe koju čine Alzheimerova bolest, oblici gubitka pamćenja i gubitak pamćenja ovisan o starosti.
The permanent-magnetic plate (2) carrying relief, engravings or cut-outs is preferably a composite material comprising a polymer as a structural binder, preferably a rubber- or plastic-like polymer, and a permanent-magnetic powder as a filler. 
Uređaj sukladno bilo kojem patentnom zahtjevu 1 do 3, naznačen time, da je permanentno magnetska ploča (2) na kojoj se nalaze reljef, gravure ili urezi izrađena od kompozitnog materijala koji sadrži polimer kao strukturno vezivno sredstvo, poželjno je polimer poput plastike ili gume i permanentno magnetski prašak kao punilo.
A glycosylated human Serum Amyloid P (SAP) protein comprising an N-linked oligosaccharide chain, wherein at least one branch of the N-linked oligosaccharide chain terminates with an a2,3-linked sialic acid moiety, wherein the SAP protein comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or variant thereof, and wherein the SAP protein inhibits the differentiation of monocytes into fibrocytes in vitro. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac 1 pri čemu barem jedna grana oligosaharidnog lanca završava s 02,3- vezanim ostatkom sijalične kiseline.
Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. 
Stručnjaci će razumijeti da uvjeti strogosti također ovise o duljini sekvencija DNA, oligonukleotidnih proba (poput onih duljine 10 baza) ili miješanih oligonukleotidnih proba.
A compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenon, or neuropathic pain in a mammal. 
Spoj prema bilo kojem od zahtjeva 1 do 11 ili njegova farmaceutski prihvatljiva sol za uporabu u postupku liječenja ili prevencije plućne fibroze, astme, kronične opstruktivne plućne bolesti (KOPB), fibroze bubrega, akutne ozljede bubrega, kronične bolesti bubrega, fibroze jetre, kožne fibroze, fibroze crijeva, raka dojke, raka gušterače, raka jajnika, raka prostate, glioblastoma, raka kostiju, raka kolona, raka crijeva, raka glave i vrata, melanoma, multiplog mijeloma, kronične limfocitne leukemije, boli kod raka, metastaza tumora, odbacivanja transplantiranog organa, skleroderme, očne fibroze, makularne degeneracije povezane s dobi (AMD), dijabetičke retinopatije, kolagene vaskularne bolesti, ateroskleroze, Raynaud-ovog fenomena ili neuropatske boli u sisavaca.
The residue was purified on the chromatotron using a 2000-micron rotor (SiO2) and 5% ethyl acetate-hexanes as eluant to afford 393 mg of the desired product as a 2:1 mixture of double bond regio-isomers. 
Ostatak se pročisti na kromatotronu uporabom 2000-mikron rotora (SiO,) i 5% etil acetat-heksana kao sredstva za eluaciju da bi se dobilo 393 mg željenog spoja kao 2:1 smjese dvostruko vezanih regio-izomera.
A device for detecting a switching operation according to claim 1, wherein the optical conductor is guided within the housing along a circular track by guiding elements, and wherein the deflecting device comprises a catch that deflects the optical conductor in a defined direction when the deflecting device is actuated such that the bending radius of the optical conductor is changed. 
Uređaj za detektiranje radnje prekidanja u skladu s patentnim zahtjevom 1, naznačen time što vodeći elementi vode optički vodič u kućištu po kružnoj putanji, gdje uređaj za skretanje sadrži zapor koji skreće optički vodič u definiranom smjeru kada se uređaj za skretanje aktuira promjenom promjera savijanja optičkog vodiča.
at least one cold water pump (7) which pumps the water in the water tank to the cold water hose (6), 
- - barem jednu pumpu hladne vode (7) koja crpi vodu iz spremnika za vodu u cijev za hladnu vodu (6),
The radial extension of the flange of the bottle is adapted to make a sealing with the inner wall of the housing at the lower surface of the rosette, thus creating a pressure chamber between the inner wall of the housing, the cylindrical wall part of the bottle, and the flange on the shoulder of the bottle. 
Radijalno širenje prirubnice boce prilagođeno je tako da pri donjoj površni rozete nastaje nepropustan spoj s unutarnjom stijenkom kućišta, i tako se stvara tlačna komora između unutarnje stijenke kućišta, cilindrične stijenke dijela boce, i prirubnice na ramenu boce.
A pharmaceutical composition comprising an antibody according to any one of claims 1 to 12, or an immunoconjugate according to claim 18, or a bispecific or multispecific molecule according to claim 19, a pharmaceutically acceptable carrier and optionally one or more further therapeutic agents. 
Farmaceutski pripravak koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 12, imunokonjugat prema zahtjevu 13, ili bispecifična ili multispecifična molekulu prema zahtjevu 14 i farmaceutski prihvatljivi nosač.
The composition according to claim 1, wherein the at least one disintegrant is crospovidone. 
Smjesa prema zahtjevu 1, gdje je barem jedno sredstvo za raspadanje krospovidon.
The method of item 2, wherein the hydrolysate is a plant hydrolysate. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je hidrolizat biljni hidrolizat ili hidrolizat soje.
A cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24. The cell of paragraph 21, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 12. The cell of paragraph 21, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 8. 
(v) anti-CD19 scFv je kodiran sekvencom SEQ ID NO: 14, signalni region 4-1BB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18; ili (v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
Vitamins that are preferred in the medium of the invention are selected from Biotin, Pantothenate, Choline chloride, Folic Acid, Myo-inositol, Niacinamide, Pyridoxine, Riboflavin, Vitamin B12, Thiamine, and Putrescine. 
Vitamini koji su preporučeni za medij sukladan izumu su biotin, pantotenat, kolin klorid, folna kiselina, mio-inozitol, niacinamid, piridoksin, riboflavin, vitamin BI2, tiamin, i putrescin.